CAP23 Abstract Program
Important Dates to Remember
January 9, 2023
Abstract submission begins at 9:00 AM CT
March 10, 2023
Abstract submission closes at 5:00 PM CT
May 30, 2023
Corresponding authors notified of submission status
August 16, 2023
Top 5 Junior Member Abstract Program winners notified
The CAP23 Abstract Program is a competitive program sponsored by the College of American Pathologists. The program is designed to promote a broad range of research in pathology. It offers pathologists and research scientists the opportunity to present original research to their peers in a poster presentation format. Editors from the Archives of Pathology & Laboratory Medicine will evaluate submissions to this program.
In addition, the CAP23 Abstract Program provides a unique opportunity for residents to enhance research skills, develop writing proficiency, gain practical experience at presenting their findings, and contribute to the literature and advancement of pathology. Accepted abstracts and case studies will be published as a web-only supplement to the September 2023 issue of the Archives. CAP junior members who have their abstracts accepted are eligible for cash awards as part of the Top 5 Junior Member Abstract Program.
While the CAP23 meeting offers in-person and virtual registration, submissions accepted for the CAP23 Abstract Program must be presented during in-person poster sessions. A virtual abstract program is not available.
Submissions are no longer being accepted.
CAP23 Abstract Program Evaluation Criteria
Abstracts will be evaluated on the following criteria:
- Significance of the hypothesis
- Valid conclusion(s)
- Argument clarity
- Presentation quality
Important Note: The number of case studies that will be accepted for the CAP23 abstract program will be significantly decreased as compared to past years. Submitting case studies that do not provide new or unique information is strongly discouraged. Case studies that merely report additional cases of a known entity will be rejected.
Case studies must include novel findings, such as the following:
- A new disease or condition (i.e. not previously reported).
- A distinctive or unusual presentation of a known disease, with one or more well-documented new findings of special clinical relevance (i.e., potentially applicable to diagnosis, therapy, prognosis, etc.) or that serves to provide new insight into the possible pathogenesis of a disease (hypothesis-generating). The new information might be derived from distinctive morphology and/or ancillary testing.
- A known disease with a demonstrated new finding using state-of-the-art techniques (immunohistochemical, molecular, 3-dimensional reconstruction, cytogenetics, etc.) relevant to a clearly stated hypothesis.
- A known disease presenting with a previously undescribed clinically or etiologically relevant association (i.e., a myelodysplastic syndrome associated with a plasma cell dyscrasia, etc.) to heighten awareness of a possible link between entities. Such a link might have been described before in one or more individual case reports, and the addition of a case might help solidify a real association.
Abstracts and case studies may be submitted to the following categories:
Autopsy and forensic pathology
Bone and soft tissue pathology
Head, neck, and oral pathology
Gastrointestinal and liver pathology
Gynecologic and placental pathology
Kidney and genitourinary pathology
Pulmonary and mediastinal pathology
Transfusion medicine and coagulation
Administrative and regulatory affairs
Corresponding authors must be available to respond to questions about the content of their submissions from the Archives editorial office, especially during the period of April 11 to May 19, 2023. Email addresses for corresponding authors must be active and accessible through August 2023.
Corresponding authors will be notified of their submission status on May 30, 2023. Authors of accepted submissions will receive specific information regarding poster presentation requirements in their acceptance notification email on May 30.
CAP Top 5 Junior Member Abstract Program
Authors of the top 5 accepted abstracts received from CAP junior members will be named as the Top 5 Junior Member Abstract Program award winners and given cash prizes:
- First place cash award = $1,500
- Second place cash award = $1,000
- Third place cash award = $750
- Fourth and fifth place cash awards are $500 each.
To be eligible for the CAP23 Top 5 Junior Member Abstract Program awards, a CAP junior member must:
- Have performed a substantial portion of the research and work involved in the preparation of the abstract;
- Be listed as either the first or second author;
- Serve as the corresponding author.
Top 5 Junior Member Abstract Program award winners will be notified by August 16, 2023.
If you have questions about the abstract program, please email email@example.com prior to completing your submission. Your questions will be routed to the abstract program coordinator.
Remember, submissions cannot be changed or resubmitted after the submission deadline. Carefully review and spell-check your abstracts and case studies prior to submission.